News

Sam Konduros, JD, Named CEO of Southeast Life Science

Roswell, GA and Greenville, SC – The Board of Directors of Southeast Life Sciences (SLS) has named Sam Konduros, Founder and President of Greenville-based SK Strategies, as Chief Executive Officer effective June 1, 2022.

Mr. Konduros succeeds Jason Rupp in the leadership role, in which Mr. Rupp served from 2019 to 2022. Mr. Rupp’s tenure included overseeing the merger of the Southeastern Medical Device Association and SE BIO in 2020.

“Vision, passion and expertise are three of the key characteristics we needed as we searched for our new leader for Southeast Life Sciences,” said Lee Burnes, SLS Board Co-Chair and Senior Vice President, Global R&D, Avanos Medical. “Those characteristics truly describe Sam and we are very fortunate to now have the benefit of his leadership in guiding Southeast Life Sciences into the future.”

Southeast Life Sciences’ mission is to cultivate, convene, and connect the Southeast entrepreneurial ecosystem to foster the public good, and life science innovation & investment across the region. The 2022 edition of the organization’s flagship event AdvanSE is May 25 – 27, 2022 at the Hotel Avalon in Alpharetta, Georgia, where Konduros will be formally introduced to stakeholders and attendees by the SLS Board leaders.\

In the past 20 years, more than 500 presenting early and late stage companies participating in advance have secured more than $7 billion in funding through nearly 800 funding transactions including 70 IPO and M&A events.

“We are incredibly proud to bring on such a dynamic leader in Sam Konduros to take Southeast Life Sciences to the next level,” said SLS Board Co-Chair and Silicon Valley Bank Director Scott McCarty. “I very much look forward to partnering with Sam to unleash his energy in furthering SLS’ mission of connecting and building the Southeast life science ecosystem.”

Mr. Konduros, who previously served as President and CEO of SCBIO and as Executive Director of the Greenville Health Research Development Corporation prior to that role, said, “I am humbly grateful for all that the SLS board, including Lee and Scott, have done to make this announcement a reality, and for their confidence in me as the organization’s next leader. I’m also appreciative of the strong and positive foundation laid by former CEO, Jason Rupp. I am incredibly eager to take the reins as CEO beginning June 1st to advance and grow the life sciences industry in the nation’s fastest growing region. The sky is truly the limit, and the rapidly approaching conference will be the ideal foundation for launching my role and ushering in SLS’s next dynamic chapter of development.”

Read more here.

Recent News

08/25/2026

United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the New Drug Application (NDA) for ralinepag to treat PAH. The FDA has set a Prescription Drug User Fee Act target action date of June 24, 2027. Ralinepag has not been approved for use in any indication by the

08/19/2026

ATCC Receives New CDC Award to Advance Influenza Testing and Surveillance

ATCC has been selected by the Centers for Disease Control and Prevention (CDC) for a new contract to support serological assays for the detection and characterization of influenza viruses. The award, valued at up to $7.3 million over the 5-year contract period (contract 75D30126C21030), will support CDC’s National Center for Immunization and Respiratory Diseases, Influenza

08/18/2026

Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™

Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of the knee, today announced that it has received regulatory approval from Panamá’s Ministry of Health to initiate its First-in-Human (FIH) clinical study in Panamá. The study will evaluate the safety and performance of Chondrograft™ in patients